Abstract

Backgroundp53 is commonly inactivated by mutations in the DNA-binding domain in a wide range of cancers. As mutant p53 often influences response to therapy, effective and rapid methods to scan for mutations in TP53 are likely to be of clinical value. We therefore evaluated the use of high resolution melting (HRM) as a rapid mutation scanning tool for TP53 in tumour samples.MethodsWe designed PCR amplicons for HRM mutation scanning of TP53 exons 5 to 8 and tested them with DNA from cell lines hemizygous or homozygous for known mutations. We assessed the sensitivity of each PCR amplicon using dilutions of cell line DNA in normal wild-type DNA. We then performed a blinded assessment on ovarian tumour DNA samples that had been previously sequenced for mutations in TP53 to assess the sensitivity and positive predictive value of the HRM technique. We also performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status.ResultsOne cell line mutation was not readily observed when exon 5 was amplified. As exon 5 contained multiple melting domains, we divided the exon into two amplicons for further screening. Sequence changes were also introduced into some of the primers to improve the melting characteristics of the amplicon. Aberrant HRM curves indicative of TP53 mutations were observed for each of the samples in the ovarian tumour DNA panel. Comparison of the HRM results with the sequencing results revealed that each mutation was detected by HRM in the correct exon. For the breast tumour panel, we detected seven aberrant melt profiles by HRM and subsequent sequencing confirmed the presence of these and no other mutations in the predicted exons.ConclusionHRM is an effective technique for simple and rapid scanning of TP53 mutations that can markedly reduce the amount of sequencing required in mutational studies of TP53.

Highlights

  • We show that high resolution melting is a highly effective scanning technique for mutations in the gene encoding p53 (TP53)

  • Amplicons for high resolution melting (HRM) analysis were designed to span each of TP53 exons 5 to 8

  • We tested the mutation detection capability of each amplicon using a panel of cancer cell lines (BT-20, SKBR3, T47D, KG-1, OVCAR-3, SW480, MDA-MB231 RPMI8226) that were homozygous or hemizygous for known TP53 mutations

Read more

Summary

Methods

We designed PCR amplicons for HRM mutation scanning of TP53 exons 5 to 8 and tested them with DNA from cell lines hemizygous or homozygous for known mutations. We performed a blinded assessment on ovarian tumour DNA samples that had been previously sequenced for mutations in TP53 to assess the sensitivity and positive predictive value of the HRM technique. We performed HRM analysis on breast tumour DNA samples with unknown TP53 mutation status. Tissue collection (AOCS) was approved by the appropriate Ethics of Human Research Committees at the Peter MacCallum Cancer Centre, Queensland Institute of Medical Research, University of Melbourne and all participating hospitals. Ovarian cancer samples with typical TP53 mutations were selected to test sensitivity and positive predictive value of the HRM methodology. The breast tumour samples were collected from patients http://www.biomedcentral.com/1471-2407/7/168 who underwent surgery at the John Radcliffe Hospital, Oxford, UK, according to the institute's ethical guidelines (approval number C02.216). The tumours underwent pathological review and genomic DNA was extracted from fresh frozen tissue. All exons with a mutation were re-amplified and re-sequenced in two directions

Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call